SG45479A1 - Synergistic treatment for parkinsonism - Google Patents

Synergistic treatment for parkinsonism

Info

Publication number
SG45479A1
SG45479A1 SG1996009888A SG1996009888A SG45479A1 SG 45479 A1 SG45479 A1 SG 45479A1 SG 1996009888 A SG1996009888 A SG 1996009888A SG 1996009888 A SG1996009888 A SG 1996009888A SG 45479 A1 SG45479 A1 SG 45479A1
Authority
SG
Singapore
Prior art keywords
parkinsonism
disease
synergistic treatment
relates
parkinson
Prior art date
Application number
SG1996009888A
Other languages
English (en)
Inventor
Bertrand L Chenard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG45479A1 publication Critical patent/SG45479A1/en

Links

Classifications

    • G—PHYSICS
    • G10—MUSICAL INSTRUMENTS; ACOUSTICS
    • G10H—ELECTROPHONIC MUSICAL INSTRUMENTS; INSTRUMENTS IN WHICH THE TONES ARE GENERATED BY ELECTROMECHANICAL MEANS OR ELECTRONIC GENERATORS, OR IN WHICH THE TONES ARE SYNTHESISED FROM A DATA STORE
    • G10H5/00—Instruments in which the tones are generated by means of electronic generators
    • G10H5/10—Instruments in which the tones are generated by means of electronic generators using generation of non-sinusoidal basic tones, e.g. saw-tooth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Multimedia (AREA)
  • Acoustics & Sound (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
SG1996009888A 1995-05-26 1996-05-24 Synergistic treatment for parkinsonism SG45479A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1995/000398 WO1996037226A2 (fr) 1995-05-26 1995-05-26 Combinaisons pour le traitement de la maladie de parkinson contenant des antagonistes de nmda
HU9601419A HUP9601419A3 (en) 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease

Publications (1)

Publication Number Publication Date
SG45479A1 true SG45479A1 (en) 1998-01-16

Family

ID=89994003

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996009888A SG45479A1 (en) 1995-05-26 1996-05-24 Synergistic treatment for parkinsonism

Country Status (26)

Country Link
US (1) US6258827B1 (fr)
EP (1) EP0828513B1 (fr)
JP (1) JPH11505828A (fr)
CN (1) CN1159325A (fr)
AT (1) ATE258067T1 (fr)
AU (1) AU696258B2 (fr)
BR (1) BR9602485A (fr)
CA (1) CA2219911C (fr)
CO (1) CO4700422A1 (fr)
CZ (1) CZ283979B6 (fr)
DE (1) DE69532482T2 (fr)
DK (1) DK0828513T3 (fr)
ES (1) ES2211904T3 (fr)
FI (1) FI974323A (fr)
HU (1) HUP9601419A3 (fr)
IL (1) IL118328A (fr)
MX (1) MX9709112A (fr)
NO (1) NO962130L (fr)
NZ (1) NZ286656A (fr)
PL (1) PL314413A1 (fr)
PT (1) PT828513E (fr)
RU (1) RU2176145C2 (fr)
SG (1) SG45479A1 (fr)
TR (1) TR199600436A2 (fr)
TW (1) TW470740B (fr)
WO (1) WO1996037226A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
HUP0004900A3 (en) * 1997-10-24 2002-03-28 Warner Lambert Co Pharmaceutical compositions for treating disease-related or drug-induced dyskinesias containing piperidine derivatives as nmda receptor antagonist as active ingredient
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6362196B1 (en) 1999-10-29 2002-03-26 Merck & Co., Inc. Method to treat pain utilizing benzimidazole NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
EP1186303A3 (fr) * 2000-09-06 2003-12-10 Pfizer Products Inc. Combinaisons pharmaceutiques pour le traitement des accidents cerebrovasculaires, contenant un facteur inhibitant la neutrophile et un antagoniste selectif du NMDA-NR2B
ATE324371T1 (de) 2001-02-23 2006-05-15 Merck & Co Inc N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
EP1436258A4 (fr) * 2001-03-08 2005-03-23 Univ Emory Antagonistes du recepteur nmda dependant du ph
EP1390034A4 (fr) 2001-04-03 2005-07-13 Merck & Co Inc Antagonistes de nmda/nr2b nonaryl-heterocyclo amidyle n-substitues
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten
WO2003062235A1 (fr) * 2002-01-17 2003-07-31 Eli Lilly And Company Modulateurs de recepteurs de l'acetylcholine
US6743921B2 (en) * 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
ES2297233T3 (es) * 2002-10-08 2008-05-01 Allergan, Inc. Uso de brimonidina en el tratamiento de demencia y enfermedad de parkinson.
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
WO2005025561A1 (fr) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions et methodes de traitement de l'intolerance orthostatique
CA2537765A1 (fr) * 2003-09-04 2005-03-17 Board Of Regents, The University Of Texas System Methodes et compositions permettant de prevenir et de traiter les troubles genito-urinaires, en particulier, l'accouchement premature et les leiomyomes
EP1588704A1 (fr) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Dérivés d'alpha-aminoamides utiles dans le traitement de l'acroparesthésie nocturne et des troubles de toxicomanie
WO2006042249A2 (fr) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methodes et compositions de traitement de la douleur de migraine
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP2008526923A (ja) * 2005-01-13 2008-07-24 ノイロサーチ アクティーゼルスカブ 新規８−置換８−アザ−ビシクロ［３．２．１］オクタン誘導体及びモノアミン神経伝達物質再取り込み阻害剤としてのそれらの使用
DK1874282T3 (da) * 2005-04-06 2010-10-25 Adamas Pharmaceuticals Inc Fremgangsmåder og præparater til behandling af CNS lidelser
US20070118044A1 (en) * 2005-07-18 2007-05-24 Mega Elektroniikka Oy Method and device for identifying; measuring and analyzing abnormal neurological responses
EP1870097A1 (fr) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Dérivés d'alpha-aminoamide pour le traitement de troubles cognitifs
RU2324492C1 (ru) * 2006-12-04 2008-05-20 Общество с ограниченной ответственностью "Березовый мир" Средство для профилактики и лечения болезни паркинсона
NZ582917A (en) 2007-06-29 2013-01-25 Univ Emory Nmda receptor antagonists for neuroprotection
CN102105169B (zh) * 2008-06-06 2014-09-10 图必制药公司 用于治疗帕金森病的药物组合物
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
WO2013156614A1 (fr) * 2012-04-20 2013-10-24 Ucb Pharma S.A. Méthodes de traitement de la maladie de parkinson
MX2016011837A (es) 2014-03-13 2017-04-27 Neuroderm Ltd Composiciones de inhibidores de la dopa decarboxilasa.
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
WO1991012005A1 (fr) 1990-02-06 1991-08-22 Pfizer Inc. Derives et analogues de 3-piperidino-4-hydroxychroman neuroprotecteurs
CZ390792A3 (en) 1991-04-18 1994-04-13 Pfizer Precursors of medicaments based on esters of phenolic 2-piperidino-1-alkanols, process of their preparation, intermediates and use
DE4118740A1 (de) 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson

Also Published As

Publication number Publication date
ATE258067T1 (de) 2004-02-15
RU2176145C2 (ru) 2001-11-27
CA2219911C (fr) 2004-07-27
HUP9601419A2 (en) 1997-09-29
CA2219911A1 (fr) 1996-11-28
TR199600436A2 (tr) 1996-12-21
TW470740B (en) 2002-01-01
CZ283979B6 (cs) 1998-07-15
JPH11505828A (ja) 1999-05-25
MX9709112A (es) 1998-02-28
EP0828513A2 (fr) 1998-03-18
CZ152496A3 (cs) 1998-04-15
DE69532482T2 (de) 2004-11-25
US6258827B1 (en) 2001-07-10
FI974323A0 (fi) 1997-11-25
HU9601419D0 (en) 1996-07-29
NZ286656A (en) 2001-03-30
AU5451996A (en) 1996-12-05
PL314413A1 (en) 1996-12-09
DK0828513T3 (da) 2004-04-13
WO1996037226A2 (fr) 1996-11-28
NO962130L (no) 1996-11-27
WO1996037226A3 (fr) 1996-12-27
FI974323A (fi) 1997-11-25
CO4700422A1 (es) 1998-12-29
CN1159325A (zh) 1997-09-17
ES2211904T3 (es) 2004-07-16
NO962130D0 (no) 1996-05-24
IL118328A (en) 2001-06-14
AU696258B2 (en) 1998-09-03
PT828513E (pt) 2004-05-31
DE69532482D1 (de) 2004-02-26
EP0828513B1 (fr) 2004-01-21
BR9602485A (pt) 1998-04-22
HUP9601419A3 (en) 1998-01-28
IL118328A0 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
SG45479A1 (en) Synergistic treatment for parkinsonism
Upton Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
ATE230989T1 (de) Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
BR9709501A (pt) Composto, composição farmacêutica , e, processos para tratar ou prevenir a esquizofrrenia e para sintetizar um composto
MY121036A (en) Piperazinyl-heterocyclic compounds in the treatment of dementia.
ATE144898T1 (de) Behandlung neurodegenerativer krankheiten
EP1212088A4 (fr) Procede de traitement de symptomes de troubles du systeme nerveux central
WO1999048489A3 (fr) Methode permettant de retarder le declenchement de la maladie d'alzheimer et de traiter ou de retarder le declenchement d'autres maladies/troubles associes a l'amylose
ATE526980T1 (de) Zusammensetzungen und verfahren zur heilung von nervengeweben
MY118944A (en) Synergistic treatment for parkinsonism
EP0383171A3 (fr) Dérivés de 2,3,23 trihydroxy-urs-12-ène pour le traitement des troubles cognitifs
PH27352A (en) 4-Benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
DE69926794D1 (de) Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen
WO2002005798A3 (fr) Compositions pharmaceutiques et leurs methodes d'utilisation
MY121206A (en) Aminobenzamide compounds for the treatment of neurodegenerative disorders
CA2246560A1 (fr) Methodes d'administration d'un antagoniste du recepteur ampa pour traiter les dyskinesies associees a la therapie par un agoniste de la dopamine
WO1994024279A3 (fr) Agents pour la prevention et le traitement de la choree de huntington et d'autres troubles neurologiques
HUT59004A (en) Process for applying the interleukine-1 biosynthesis of 3-substituted-2-oxyndole-derivatives carried out as inhibitor